MoU promoting globalisation of clinical trial signed

The MoU will implement the first multi-centre clinical trial project.

A Memorandum of Understanding developing clinical trials was jointly signed by The Greater Bay Area International Clinical Trial Institute of Hong Kong (GBAICTI), the Greater Bay Area International Clinical Trials Centre of Shenzhen (BAY TRIAL), and Immuno Cure BioTech in Shenzhen on 29 July.

The collaboration promotes the globalisation of clinical trials in the Guangdong-Hong Kong-Macao Greater Bay Area.

It will also implement the first cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic HIV DNA vaccine jointly developed by Immuno Cure and the University of Hong Kong AIDS centre.

The GBAICTI and BAY TRIAL also plans to establish the GBA Clinical Trial Collaboration Platform by the end of this year, offering a range of services including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials.